Dengue is a neglected disease mainly affecting tropical and subtropical countries. The diagnosis of dengue fever is still a problem since most of it is made from whole or recombinant DENV proteins, which present cross-reactions with other members of the Flavivirus family. Therefore, there is still a huge demand for new diagnostic methods that provide rapid, low-cost, easy-to-use confirmation. Thus, in this study, we developed an affordable electrochemical biosensor for rapidly detecting immunoglobulin G (IgG) serological antibodies in the sera of DENV-infected patients. An identified linear B-cell epitope (DENV/18) specific for DENV 1–4 serotypes recognized by IgG in patient sera was selected as a target molecule after a microarray of peptides using the SPOT-synthesis methodology. After chemical synthesis, the DENV/18-peptide was immobilized on the surface of the working electrode of a commercially available screen-printed gold electrode (SPGE). The capture of DENV-specific IgG allowed for the formation of an immunocomplex that was measured by cyclic voltammetry (CV) and differential pulse voltammetry (DPV) using a potassium ferrocyanide/ferricyanide ([Fe(CN)₆]^3−/4−) electrochemical probe. An evaluation of the biosensor’s performance showed a detection limit of 100 µg mL⁻¹ for the synthetic peptides (DENV/18) and 1.21 ng mL⁻¹ in CV and 0.43 ng mL⁻¹ in DPV for human serum, with a sensitivity of 7.21 µA in CV and 8.79 µA in DPV. The differentiation of infected and uninfected individuals was possible even at a high dilution factor that reduced the required sample volumes to a few microliters. The final device proved suitable for diagnosing DENV by analyzing real serum samples, and the results showed good agreement with molecular biology diagnostics. The flexibility to conjugate other antigenic peptides to SPEs suggests that this technology could be rapidly adapted to diagnose other pathogens.

The increasing demand for advanced diagnostic technologies has positioned biosensor platforms as powerful alternatives to conventional analytical methods. Among them, lateral flow platforms (LFPs) are widely used for their speed, simplicity, and low cost. However, their limited sensitivity and lack of quantitative precision have spurred the development of enhanced systems incorporating electrochemical detection. Electrochemical biosensors offer significant advantages, including high sensitivity, excellent selectivity, and ease of miniaturization, which make them especially suitable for point-of-care testing (POCT). To address the limitations of traditional colorimetric LFPs, several strategies have been employed, such as the incorporation of nanomaterials, enzymatic amplification, and signal-enhancing labels. A particularly promising innovation is the direct integration of electrodes into LFPs, enabling real-time electrochemical readouts and enhanced analytical accuracy. Despite their potential, challenges persist, including manufacturing complexity, a lack of standardized protocols, and difficulties in scaling production for widespread adoption. Continued progress in developing hybrid platforms that combine lateral flow technology with electrochemical detection is crucial for expanding diagnostic applications in healthcare, environmental monitoring, and food safety. This work explores recent advances in electrochemical LFPs, reviewing current methodologies while discussing their advantages, limitations, and the future directions necessary to facilitate broader implementation and improve global diagnostic accessibility.